Clinical trial designs for predictive marker validation in cancer treatment trials.
暂无分享,去创建一个
Daniel J Sargent | Laurence Collette | L. Collette | D. Sargent | B. Conley | C. Allegra | Barbara A Conley | Carmen Allegra
[1] M. Hammond,et al. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. , 2002, Seminars in oncology.
[2] N. Magné,et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] V. Catalano,et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[5] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[6] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[7] D. Sargent,et al. Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.
[8] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[9] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[10] Daniel F. Hayes,et al. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.
[11] F. Goldwasser,et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Maley,et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H E Rockette,et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Groshen,et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[16] W. L. McGuire,et al. Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.
[17] D. G. Altman,et al. Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.
[18] M. Buyse,et al. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Børresen-Dale,et al. TP53 and breast cancer , 2003, Human mutation.
[20] M. Gnant,et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] S. Groshen,et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.